

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 210174.401USPC	APPLICATION NO. 10/574,438
	APPLICANTS Raymond Nadeson et al.	
	FILING DATE June 25, 2007	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,778,799 B2	10/18/88	Tibes et al.	514	277	
	AB	5,521,178 A1	05/28/96	Nickel et al.	514	231.2	
	AC	6,221,395 B1	04/24/01	Maggi et al.	424	475	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION IF APPROPRIATE	
					YES	NO
	AD	CA 2,314,746 A1	02/03/01	Canada		
	AE	CA 2,102,072 C	05/01/94	Canada		
	AF	CN 1399550A	02/26/03	China (+ English Abstract)		X
	AG	EP 207 193 A2	01/07/87	EPO		X
	AH	EP 595 311 A1	05/04/94	EPO		
	AI	EP 795 324 A2	09/17/97	EPO		X
	AJ	WO 01/08682 A2	02/08/01	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AK	Chi et al., "A Study on in vitro Drug Release Pattern of Multi-layered Controlled-Release Matrix Tablets Containing Tramadol Hydrochloride," <i>Journal of Shenyang Pharmaceutical University</i> 18(2): 88-90, March 2001.
AL	Friedel et al., "Flupirtine. A review of it's pharmacological properties, and therapeutic efficacy in pain states," <i>Drugs</i> 45(4): 548-569, 1993.
AM	Gribkoff, "The therapeutic potential of neuronal KCNQ channel modulators," <i>Expert Opinion on Therapeutic Targets</i> 7(6): 737-748, December 2003.
AN	Herrmann et al., "On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic states in arthrosis or arthritis," <i>Postgraduate Medical Journal</i> 63: 87-103, 1987.
AO	Li et al., "Recent Pharmacology Progress in Flupirtine, A new Analgesic Agent," <i>Chinese Journal of New Drugs</i> 11(10): 759-763, October 1, 2002 (+ English Translation).
AO	Nickel, "Pharmacological activity of flupirtine in combination with morphine," <i>Regional Anesthesia</i> 18(45): page 4, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 210174.401USPC	APPLICATION NO. 10/574,438
	APPLICANTS Raymond Nadeson et al.	
	FILING DATE June 25, 2007	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,610,324 B2	08/26/03	Stoll	424	464	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Schuster et al., "Flupirtine: A review of its neuroprotective and behavioural properties," <i>CNS Drug Reviews</i> 4(2): 149-164, 1998.
AQ	Yu Jin-gui et al., "Enhanced Analgesia Effect of NMDA Receptor Antagonist on Opium," <i>Foreign Medical Sciences – Anesthesiology and Resuscitation</i> 20(2): 85-87, 1990 (English translation only).
AR	International Search Report for PCT/AU2004/001772, mailed March 1, 2005, 5 pages.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).